Javascript must be enabled to continue!
Functional Development of the Ovarian Noradrenergic Innervation
View through CrossRef
A substantial fraction of the noradrenergic innervation targeting the mammalian ovary is provided by neurons of the celiac ganglion. Although studies in the rat have shown that noradrenergic nerves reach the ovary near the time of birth, it is unknown how the functional capacity of this innervation unfolds during postnatal ovarian development. To address this issue, we assessed the ability of the developing ovary to incorporate and release 3H-norepinephrine. Incorporation of 3H-norepinephrine was low during the first 3 wk of postnatal life, but pharmacological inhibition of norepinephrine (NE) neuronal uptake with cocaine showed that an intact transport mechanism for NE into nerve terminals is already in place by the first week after birth. Consistent with this functional assessment, the mRNA encoding the NE transporter was also expressed in the celiac ganglion at this time. During neonatal-infantile development [postnatal (PN) d 5–20], the spontaneous, vesicle-independent outflow of recently taken up NE was high, but the NE output in response to K+-induced depolarization was low. After PN d 20, spontaneous outflow decreased and the response to K+ increased markedly, reaching maximal values by the time of puberty. Tyramine-mediated displacement of NE stored in vesicles, which displace vesicular NE, showed that vesicle-dependent NE storage becomes functional by PN d 12 and that vesicular release increases during the juvenile-peripubertal phases of sexual development. These results indicate that vesicular release of NE from ovarian noradrenergic nerves begins to operate by the third week of postnatal life, becoming fully functional near the time of puberty.
The Endocrine Society
Title: Functional Development of the Ovarian Noradrenergic Innervation
Description:
A substantial fraction of the noradrenergic innervation targeting the mammalian ovary is provided by neurons of the celiac ganglion.
Although studies in the rat have shown that noradrenergic nerves reach the ovary near the time of birth, it is unknown how the functional capacity of this innervation unfolds during postnatal ovarian development.
To address this issue, we assessed the ability of the developing ovary to incorporate and release 3H-norepinephrine.
Incorporation of 3H-norepinephrine was low during the first 3 wk of postnatal life, but pharmacological inhibition of norepinephrine (NE) neuronal uptake with cocaine showed that an intact transport mechanism for NE into nerve terminals is already in place by the first week after birth.
Consistent with this functional assessment, the mRNA encoding the NE transporter was also expressed in the celiac ganglion at this time.
During neonatal-infantile development [postnatal (PN) d 5–20], the spontaneous, vesicle-independent outflow of recently taken up NE was high, but the NE output in response to K+-induced depolarization was low.
After PN d 20, spontaneous outflow decreased and the response to K+ increased markedly, reaching maximal values by the time of puberty.
Tyramine-mediated displacement of NE stored in vesicles, which displace vesicular NE, showed that vesicle-dependent NE storage becomes functional by PN d 12 and that vesicular release increases during the juvenile-peripubertal phases of sexual development.
These results indicate that vesicular release of NE from ovarian noradrenergic nerves begins to operate by the third week of postnatal life, becoming fully functional near the time of puberty.
Related Results
Noradrenergic and peptidergic innervation of lymphoid tissue
Noradrenergic and peptidergic innervation of lymphoid tissue
Abstract
Sympathetic noradrenergic nerve fibers innervate both the vasculature and parenchymal fields of lymphocytes and associated cells in several lymphoid organs,...
Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System
Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System
BACKGROUND:
The tricyclic antidepressant amitriptyline, the serotonin and noradrenaline reuptake inhibitor duloxetine, and gabapentinoids are first-line drugs for treat...
P–688 Assessment of ovarian vascularity by three-dimensional vaginal power Doppler on day two of menstrual cycle to predict the number of mature eggs collected
P–688 Assessment of ovarian vascularity by three-dimensional vaginal power Doppler on day two of menstrual cycle to predict the number of mature eggs collected
Abstract
Study question
Could ovarian vascularity indices, measured by 3-dimensional (3D) vaginal power Doppler, predict the num...
Fluorescence Histochemical Studies on the Noradrenergic Innervation of the Canine Larynx
Fluorescence Histochemical Studies on the Noradrenergic Innervation of the Canine Larynx
The origin and course of noradrenergic nerve fibers contained in laryngeal nerves and their destinations in the larynx of the dog were investigated using fluorescence histochemistr...
P-677 fasting-mimicking diet delays ovarian aging by modulating immune cells and enhancing glycocholic acid levels
P-677 fasting-mimicking diet delays ovarian aging by modulating immune cells and enhancing glycocholic acid levels
Abstract
Study question
Does fasting-mimicking diet (FMD) alleviate ovarian aging in mice, and what roles do gut and serum metab...
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Abstract
Background
2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct enti...
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract
Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...
Abstract MIP-048: SHORT-FORM RON KINASE AS A NOVEL THERAPEUTIC TARGET IN OVARIAN CANCER
Abstract MIP-048: SHORT-FORM RON KINASE AS A NOVEL THERAPEUTIC TARGET IN OVARIAN CANCER
Abstract
BACKGROUND: Although 70–80% of women respond to standard platinum-based chemotherapy, a majority of patients will develop recurrent platinum-resistant disea...

